What does this research mean for the field?

Elevated circulating TMAO is associated with adverse outcomes in heart failure, but its prognostic value is confounded by renal function, and it currently remains a prognostic risk marker rather than a validated clinical target. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Synthesize clinical evidence regarding the gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) and parallel gut metabolites across the gut–heart–kidney axis in heart failure.

September 15, 2026BiomedicinesOpen Access

The Gut–Heart–Kidney Axis in Heart Failure: Trimethylamine N-Oxide and Beyond—A State-of-the-Art Review

View Full Paper

Ask AI

Bookmark

Authors

IYIsmaila Ajayi Yusuf SASolomon Anighoro ASAbdullah Sultany

Discussion

Member takes

Overview

Narrative review reveals elevated trimethylamine N-oxide links to adverse outcomes in heart failure, indicating gut microbial pathways represent an unaddressed cardiorenal therapeutic target.

Key Points

Synthesize clinical evidence regarding the gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) and parallel gut metabolites across the gut–heart–kidney axis in heart failure.
Reviewed 14 observational studies comprising 13 prospective cohorts and one cross-sectional analysis across diverse heart failure settings.
Evaluated cohorts spanning chronic heart failure, acute decompensated heart failure, incident heart failure in community samples, and subclinical myocardial injury.
Elevated circulating TMAO consistently associated with increased risk of all-cause mortality, rehospitalization, and major adverse cardiovascular events, though associations attenuated after adjusting for renal function.
Guideline-directed medical therapy uptitration in the BIOSTAT-CHF cohort failed to lower TMAO levels, suggesting an unaddressed gut dysbiosis pathway.
Emerging parallel gut metabolites, including phenylacetylglutamine and short-chain fatty acids, support multimetabolite profiling, but prospective interventional trials demonstrating cardiovascular benefit from lowering TMAO remain absent.

Cite This Study

Yusuf et al. (2026) studied this question.

synapsesocial.com/papers/6aa913f39013453be30a24f9 https://doi.org/10.3390/biomedicines14092054

View Full Paper

Ask AI

Bookmark

September 15, 2026BiomedicinesOpen Access

The Gut–Heart–Kidney Axis in Heart Failure: Trimethylamine N-Oxide and Beyond—A State-of-the-Art Review

View Full Paper

Ask AI

Bookmark

Authors

IYIsmaila Ajayi Yusuf SASolomon Anighoro ASAbdullah Sultany

Discussion

Member takes

Overview

Narrative review reveals elevated trimethylamine N-oxide links to adverse outcomes in heart failure, indicating gut microbial pathways represent an unaddressed cardiorenal therapeutic target.

Key Points

Synthesize clinical evidence regarding the gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) and parallel gut metabolites across the gut–heart–kidney axis in heart failure.
Reviewed 14 observational studies comprising 13 prospective cohorts and one cross-sectional analysis across diverse heart failure settings.
Evaluated cohorts spanning chronic heart failure, acute decompensated heart failure, incident heart failure in community samples, and subclinical myocardial injury.
Elevated circulating TMAO consistently associated with increased risk of all-cause mortality, rehospitalization, and major adverse cardiovascular events, though associations attenuated after adjusting for renal function.
Guideline-directed medical therapy uptitration in the BIOSTAT-CHF cohort failed to lower TMAO levels, suggesting an unaddressed gut dysbiosis pathway.
Emerging parallel gut metabolites, including phenylacetylglutamine and short-chain fatty acids, support multimetabolite profiling, but prospective interventional trials demonstrating cardiovascular benefit from lowering TMAO remain absent.

Cite This Study

Yusuf et al. (2026) studied this question.

synapsesocial.com/papers/6aa913f39013453be30a24f9 https://doi.org/10.3390/biomedicines14092054

View Full Paper

Ask AI

Bookmark